Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alector
Biotech
GSK’s $700M Alector bet blows up with 2nd Alzheimer’s fail
GSK and Alector stopped a phase 2 trial of their Alzheimer’s drug after an interim analysis found the study was unlikely to hit its primary endpoint.
Nick Paul Taylor
Apr 30, 2026 5:15am
Alector halves staff after GSK-partnered antibody fails in ph. 3
Oct 22, 2025 11:23am
Alector lays off 17% of staff after ph. 2 Alzheimer's drug fail
Nov 26, 2024 4:50am
AbbVie dumps Alector's Alzheimer's immunotherapy after phase 1
Jul 8, 2022 6:04am
With GSK, Alector to capitalize on big moment in Alzheimer's
Jan 27, 2022 9:35am
COVID-19 vaccine mandates a mixed bag in biotech
Aug 11, 2021 8:10am
